Theriva Biologics Reaches Agreement with FDA on VCN-01 Phase 3 Trial Design
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 23 2026
0mins
Should l Buy TOVX?
Theriva Biologics announced the outcomes of a recent Type B End-of-Phase 2 meeting with the FDA regarding the design of a Phase 3 clinical study of lead clinical candidate VCN-01 in combination with standard-of-care chemotherapy for the treatment of metastatic pancreatic adenocarcinoma. The FDA provided general agreement with Theriva's proposed design for a Phase 3 clinical trial, which closely tracks the design of the successful VIRAGE Phase 2 trial. As announced in 2025, the VIRAGE trial met its primary endpoints, with metastatic PDAC patients receiving VCN-01 with SoC chemotherapy having improved overall survival, progression free survival and Duration of Response compared to SoC chemotherapy alone. Greater improvements in OS and PFS were observed in patients who received two doses of VCN-01, leading Theriva to plan the Phase 3 trial to include repeat dosing and an adaptive design aimed to optimize the trial's timelines and outcomes. Consistent with scientific advice previously received from the Committee for Medicinal Products for Human Use of the European Medicines Agency, the FDA advised that a potential biologics licensing application for VCN-01 in metastatic PDAC could be supported by Theriva's proposed Phase 3 clinical trial comprising a single, high-quality, randomized, double-blinded, study comparing VCN-01 plus gemcitabine/nab-paclitaxel SoC to gemcitabine/nab-paclitaxel SoC plus placebo. The FDA further agreed on the proposed dosing of VCN-01 and gemcitabine/nab-paclitaxel in repeated "macrocycles", the proposed inclusion/exclusion criteria, the primary endpoint (overall survival), key secondary endpoints, and the use of an adaptive design. The FDA also clarified statistical expectations regarding the proposed interim analyses and the quality of data required for potential sample size re-estimation or a demonstration of early efficacy.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TOVX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TOVX
About TOVX
Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a new oncolytic adenovirus platform. The Company’s candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a physical and immunosuppressive barrier to cancer treatment; SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci), and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Theriva Biologics Reports Q1 Financial Results and Milestones
- Narrowed Financial Loss: Theriva Biologics reported a net loss of $2.04 million for Q1, significantly down from $4.32 million in the previous year, indicating improved cost management and operational efficiency, which may bolster investor confidence.
- Strong Cash Position: As of March 31, 2026, the company had $14.4 million in cash and cash equivalents, expected to sustain operations into Q1 2027, ensuring continued investment in clinical trials and R&D.
- Clinical Trial Progress: Theriva has aligned with the FDA on the Phase 3 trial design for VCN-01 targeting metastatic pancreatic ductal adenocarcinoma, planning a small feasibility study in Spain to validate the efficacy of more frequent dosing, thus advancing product development.
- Future Outlook: Should the FDA approve the submitted protocol, the first patient is expected to be enrolled in December 2026, with a rolling Biologics License Application (BLA) submission anticipated in 2029, laying the groundwork for future market access.
See More
Theriva Biologics Q1 Financial Overview
- Earnings Report: Theriva Biologics reported a Q1 GAAP EPS of -$0.05, aligning with market expectations, indicating the company's ongoing efforts toward financial stability.
- Revenue Insights: The company generated $0.3 million in revenue during Q1, reflecting initial market acceptance of its products and potential growth opportunities despite the low figures.
- Cash Position: As of March 31, 2026, Theriva Biologics had cash and cash equivalents of $14.4 million, providing a cash runway into Q1 2027, ensuring short-term financial security for operations.
- Future Outlook: The current cash reserves position the company well for future growth, particularly in R&D and marketing, potentially laying the groundwork for subsequent product launches and market expansion.
See More
Theriva Biologics Presents New Data at AACR Meeting
- Clinical Trial Progress: Theriva Biologics is set to present subgroup analyses from the VIRAGE study at the 2026 AACR Annual Meeting, focusing on the efficacy of VCN-01 combined with gemcitabine and nab-paclitaxel in newly diagnosed metastatic pancreatic cancer patients, highlighting improved outcomes across multiple patient groups.
- Therapeutic Innovation: VCN-01 is a systemically administered oncolytic adenovirus designed to selectively replicate within tumor cells and degrade tumor stroma, thereby enhancing chemotherapy effectiveness, increasing tumor immunogenicity, and exposing cancer cells to the patient's immune system.
- FDA and EMA Collaboration: Theriva has aligned with both the FDA and EMA on plans for a pivotal Phase 3 trial to evaluate multiple dosing regimens of VCN-01 in first-line metastatic pancreatic ductal adenocarcinoma, demonstrating the company's strategic commitment to advancing new therapies.
- Market Performance: TOVX stock has traded between $0.16 and $1.50 over the past year, closing at $0.25, up 1.94%, and further rising 79.08% in after-hours trading, reflecting positive market expectations for the new therapy.
See More
Theriva Biologics Presents VCN-01 Clinical Data at AACR
- Clinical Trial Results: Theriva Biologics will present tumor response and biomarker data from the VIRAGE Phase 2b clinical trial at the AACR Annual Meeting on April 20, 2026, indicating that VCN-01 combined with gemcitabine/nab-paclitaxel significantly improves treatment outcomes in newly diagnosed metastatic pancreatic cancer patients, potentially offering new hope in this field.
- Immune-Mediated Mechanism: The data supports an immune-mediated mode of action for VCN-01, consistent with previous clinical observations, showing that patients treated with VCN-01 experienced significantly prolonged response duration and survival, laying the groundwork for future Phase 3 trials that could redefine treatment standards for metastatic pancreatic cancer.
- FDA and EMA Alignment: Theriva has achieved alignment with both the FDA and EMA on a proposed Phase 3 clinical trial to evaluate VCN-01 in combination with chemotherapy, which will provide crucial support for the company's future drug registration and market launch efforts.
- Future Research Plans: The company is also planning a small study to assess whether more frequent and extended dosing of VCN-01 could further improve patient outcomes, demonstrating Theriva's ongoing commitment to optimizing treatment regimens and enhancing patient survival rates.
See More
Theriva Biologics Advances VCN-01 to Phase 3 Clinical Trial
- FDA Meeting Outcomes: Theriva's meeting with the FDA confirmed the design of a Phase 3 clinical trial for VCN-01 in combination with standard chemotherapy for metastatic pancreatic cancer, marking a significant advancement in cancer treatment.
- Optimized Trial Design: The FDA-supported Phase 3 trial will utilize repeat dosing and an adaptive design aimed at optimizing timelines and outcomes, which is expected to further enhance patient overall survival and progression-free survival rates.
- Funding and Partnership Opportunities: With combined feedback from the FDA and EMA, Theriva can finalize the protocol for the Phase 3 clinical trial and actively pursue strategic funding and partnerships to advance the development of this new therapy.
- Significant Market Potential: VCN-01, as an oncolytic virus, has a unique mechanism of action that enhances chemotherapy effectiveness, and it is anticipated to provide a novel and effective treatment option for patients with difficult-to-treat pancreatic cancer, presenting substantial market potential.
See More
Theriva Biologics Reports FY GAAP EPS of -$2.08
- Financial Performance: Theriva Biologics reported a fiscal year GAAP EPS of -$2.08, indicating challenges in profitability that could impact investor confidence and future fundraising capabilities.
- Cash Flow Status: As of December 31, 2025, the company's cash and cash equivalents totaled $13.1 million, an increase from $11.6 million in 2024, suggesting some improvement in liquidity.
- Recent Cash Position: As of February 26, 2026, Theriva Biologics had approximately $15.2 million in cash, indicating a short-term improvement in funding that may support ongoing operations.
- Market Reaction Outlook: Despite the cash flow improvement, the continued negative earnings may raise concerns about the company's future growth potential, affecting stock performance and investor confidence.
See More
Theriva Biologics Reports Q1 Financial Results and Milestones
- Narrowed Financial Loss: Theriva Biologics reported a net loss of $2.04 million for Q1, significantly down from $4.32 million in the previous year, indicating improved cost management and operational efficiency, which may bolster investor confidence.
- Strong Cash Position: As of March 31, 2026, the company had $14.4 million in cash and cash equivalents, expected to sustain operations into Q1 2027, ensuring continued investment in clinical trials and R&D.
- Clinical Trial Progress: Theriva has aligned with the FDA on the Phase 3 trial design for VCN-01 targeting metastatic pancreatic ductal adenocarcinoma, planning a small feasibility study in Spain to validate the efficacy of more frequent dosing, thus advancing product development.
- Future Outlook: Should the FDA approve the submitted protocol, the first patient is expected to be enrolled in December 2026, with a rolling Biologics License Application (BLA) submission anticipated in 2029, laying the groundwork for future market access.
See More
Theriva Biologics Q1 Financial Overview
- Earnings Report: Theriva Biologics reported a Q1 GAAP EPS of -$0.05, aligning with market expectations, indicating the company's ongoing efforts toward financial stability.
- Revenue Insights: The company generated $0.3 million in revenue during Q1, reflecting initial market acceptance of its products and potential growth opportunities despite the low figures.
- Cash Position: As of March 31, 2026, Theriva Biologics had cash and cash equivalents of $14.4 million, providing a cash runway into Q1 2027, ensuring short-term financial security for operations.
- Future Outlook: The current cash reserves position the company well for future growth, particularly in R&D and marketing, potentially laying the groundwork for subsequent product launches and market expansion.
See More
Theriva Biologics Presents New Data at AACR Meeting
- Clinical Trial Progress: Theriva Biologics is set to present subgroup analyses from the VIRAGE study at the 2026 AACR Annual Meeting, focusing on the efficacy of VCN-01 combined with gemcitabine and nab-paclitaxel in newly diagnosed metastatic pancreatic cancer patients, highlighting improved outcomes across multiple patient groups.
- Therapeutic Innovation: VCN-01 is a systemically administered oncolytic adenovirus designed to selectively replicate within tumor cells and degrade tumor stroma, thereby enhancing chemotherapy effectiveness, increasing tumor immunogenicity, and exposing cancer cells to the patient's immune system.
- FDA and EMA Collaboration: Theriva has aligned with both the FDA and EMA on plans for a pivotal Phase 3 trial to evaluate multiple dosing regimens of VCN-01 in first-line metastatic pancreatic ductal adenocarcinoma, demonstrating the company's strategic commitment to advancing new therapies.
- Market Performance: TOVX stock has traded between $0.16 and $1.50 over the past year, closing at $0.25, up 1.94%, and further rising 79.08% in after-hours trading, reflecting positive market expectations for the new therapy.
See More
Theriva Biologics Presents VCN-01 Clinical Data at AACR
- Clinical Trial Results: Theriva Biologics will present tumor response and biomarker data from the VIRAGE Phase 2b clinical trial at the AACR Annual Meeting on April 20, 2026, indicating that VCN-01 combined with gemcitabine/nab-paclitaxel significantly improves treatment outcomes in newly diagnosed metastatic pancreatic cancer patients, potentially offering new hope in this field.
- Immune-Mediated Mechanism: The data supports an immune-mediated mode of action for VCN-01, consistent with previous clinical observations, showing that patients treated with VCN-01 experienced significantly prolonged response duration and survival, laying the groundwork for future Phase 3 trials that could redefine treatment standards for metastatic pancreatic cancer.
- FDA and EMA Alignment: Theriva has achieved alignment with both the FDA and EMA on a proposed Phase 3 clinical trial to evaluate VCN-01 in combination with chemotherapy, which will provide crucial support for the company's future drug registration and market launch efforts.
- Future Research Plans: The company is also planning a small study to assess whether more frequent and extended dosing of VCN-01 could further improve patient outcomes, demonstrating Theriva's ongoing commitment to optimizing treatment regimens and enhancing patient survival rates.
See More
Theriva Biologics Advances VCN-01 to Phase 3 Clinical Trial
- FDA Meeting Outcomes: Theriva's meeting with the FDA confirmed the design of a Phase 3 clinical trial for VCN-01 in combination with standard chemotherapy for metastatic pancreatic cancer, marking a significant advancement in cancer treatment.
- Optimized Trial Design: The FDA-supported Phase 3 trial will utilize repeat dosing and an adaptive design aimed at optimizing timelines and outcomes, which is expected to further enhance patient overall survival and progression-free survival rates.
- Funding and Partnership Opportunities: With combined feedback from the FDA and EMA, Theriva can finalize the protocol for the Phase 3 clinical trial and actively pursue strategic funding and partnerships to advance the development of this new therapy.
- Significant Market Potential: VCN-01, as an oncolytic virus, has a unique mechanism of action that enhances chemotherapy effectiveness, and it is anticipated to provide a novel and effective treatment option for patients with difficult-to-treat pancreatic cancer, presenting substantial market potential.
See More
Theriva Biologics Reports FY GAAP EPS of -$2.08
- Financial Performance: Theriva Biologics reported a fiscal year GAAP EPS of -$2.08, indicating challenges in profitability that could impact investor confidence and future fundraising capabilities.
- Cash Flow Status: As of December 31, 2025, the company's cash and cash equivalents totaled $13.1 million, an increase from $11.6 million in 2024, suggesting some improvement in liquidity.
- Recent Cash Position: As of February 26, 2026, Theriva Biologics had approximately $15.2 million in cash, indicating a short-term improvement in funding that may support ongoing operations.
- Market Reaction Outlook: Despite the cash flow improvement, the continued negative earnings may raise concerns about the company's future growth potential, affecting stock performance and investor confidence.
See More
